Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
Operating Margin
Tonix Pharmaceuticals Holding Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
307.8m USD |
-722%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
330.5B USD |
30%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.4B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
137.2B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
127.8B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.7B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Tonix Pharmaceuticals Holding Corp
Glance View
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 73 full-time employees. The company went IPO on 2010-03-29. The company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Tonix Pharmaceuticals Holding Corp's most recent financial statements, the company has Operating Margin of -721.5%.
You don't have any saved screeners yet